Suppr超能文献

奥曲肽与血管加压素治疗术中类癌危象的比较。

Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis.

机构信息

Department of Basic Medical Sciences, College of Osteopathic Medicine of the Pacific-Northwest, Western University of Health Sciences, Lebanon, OR, USA.

Division of Surgical Oncology, Department of Surgery, Oregon Health & Science University, Portland, OR, USA.

出版信息

Ann Surg Oncol. 2024 May;31(5):2996-3002. doi: 10.1245/s10434-023-14876-4. Epub 2024 Jan 16.

Abstract

BACKGROUND

Intraoperative carcinoid crisis is typically sudden onset of profound hypotension during operations on patients with neuroendocrine tumors. The crisis was thought to be due to massive release of hormones, and perioperative octreotide was recommended as a prophylaxis against the crisis and as first-line treatment. Recent studies show that octreotide does not prevent the crisis and that no massive release of hormones occurs. Therefore, the authors hypothesized that octreotide is not effective for treating the crisis.

METHODS

A prospective carcinoid anesthesia database was analyzed for occurrences of crisis. Outcomes were compared between protocols when first-line therapy was bolus octreotide and when it was vasopressors without octreotide. Significance was determined by Student's t test, the Mann-Whitney U test, and Fisher's exact test.

RESULTS

Among operations performed with octreotide as first-line treatment (n = 150), crisis occurred for 45 (30 %) patients, the median crisis duration was 6 min, 12 (27 %) patients had crises longer than 10 min, 42 patients (93 %) required subsequent vasopressor administration to resolve the crisis, and 3 (2 %) operations were aborted. Among operations performed with vasopressors as the first-line treatment (n = 195), crisis occurred for 49 (25 %) patients (p = 0.31), the median crisis duration was 3 min (p < 0.001), and no crisis lasted longer than 10 min (p = 0.001). Patients treated with vasopressors were less likely to have multiple crises and had a shorter total time in crisis, a shorter anesthesia time, and no aborted operations (p < 0.05 for all).

CONCLUSIONS

First-line octreotide was ineffective treatment for carcinoid crisis, with patients requiring vasopressors to resolve the crisis, and many crises lasting longer than 10 min. First-line vasopressor treatment resulted in significantly shorter crisis durations, fewer crises and aborted operations, and shorter anesthesia times. Vasopressors should be used as first-line treatment for intraoperative crisis, and treatment guidelines should be changed.

摘要

背景

术中类癌危象通常是在对神经内分泌肿瘤患者进行手术时突然出现严重低血压。该危象被认为是由于激素大量释放引起的,因此建议在围手术期使用奥曲肽作为预防该危象的措施和一线治疗方法。最近的研究表明,奥曲肽不能预防该危象,也不会发生激素的大量释放。因此,作者假设奥曲肽对该危象无效。

方法

对前瞻性类癌麻醉数据库中发生的危象进行了分析。当一线治疗药物为奥曲肽推注时,与当一线治疗药物为血管加压素而不使用奥曲肽时,比较了两组方案的结果。采用学生 t 检验、Mann-Whitney U 检验和 Fisher 确切概率法确定显著性。

结果

在使用奥曲肽作为一线治疗药物的手术中(n = 150),有 45 例(30%)患者发生危象,中位危象持续时间为 6 分钟,12 例(27%)患者的危象持续时间超过 10 分钟,42 例(93%)患者需要随后使用血管加压素来缓解危象,3 例(2%)手术被取消。在使用血管加压素作为一线治疗药物的手术中(n = 195),有 49 例(25%)患者发生危象(p = 0.31),中位危象持续时间为 3 分钟(p < 0.001),且没有危象持续时间超过 10 分钟(p = 0.001)。使用血管加压素治疗的患者发生多次危象的可能性较低,且总危象持续时间、麻醉时间较短,且无手术取消(p < 0.05)。

结论

奥曲肽作为一线治疗药物对类癌危象无效,需要使用血管加压素来缓解危象,而且许多危象持续时间超过 10 分钟。一线血管加压素治疗可显著缩短危象持续时间,减少危象和手术取消次数,缩短麻醉时间。血管加压素应作为术中危象的一线治疗药物,治疗指南应进行更改。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验